

From: Wood, Lorraine
Sent: Wednesday, April 26, 2017 12:15 PM
To: MaryAnn Lamb <MaryAnn.Lamb@bpl-us.com>
Subject: Information Request for BLA 125644: Sections 3.2
Importance: High

Dear Dr. Lamb,

We are reviewing your submission for BLA 125644 Human Albumin Solution (HAS) 5% and 25% and we request the following information to continue our review:

- 1) Section 3.2.S.3.1 ((b) (4) [REDACTED] and other characteristics):
 - a) Please provide all raw data including (b) (4) [REDACTED] used to determine (b) (4) [REDACTED] of drug substance.
 - b) Please provide a detailed description of how (b) (4) [REDACTED] performs (b) (4) [REDACTED] for determining (b) (4) [REDACTED]
- 2) Section 3.2.S.3.2 (Impurities)
 - a) Please provide raw data including figures representing (b) (4) [REDACTED] for the (b) (4) [REDACTED] step used to remove impurities.
 - b) Please provide raw data for the (b) (4) [REDACTED] assay for each impurity. Include standard curve data used to quantify each impurity.
- 3) Section 3.2.S.4 (Specifications)
 - a) Please provide a detailed justification for specifications related to (b) (4) [REDACTED] (Table 1).
 - b) Please provide raw data and figures for batch Process QC results listed Tables 3 and 6.
- 4) Section 3.2.S.7 (Stability Summary and Conclusions)
 - a) The stability summary and conclusions are incomplete. Only 5% HAS drug substance stability data (representing (b) (4) [REDACTED]) has been submitted for (b) (4) [REDACTED] time intervals up to (b) (4) [REDACTED]. Long term stability studies should be performed for both 5% and 25% HAS under normal and accelerated storage conditions. If available please provide long

term stability data for both 5% and 25% HAS drug substance with parameters, temperature conditions and time points in accordance with ICH guidelines.

5) Section 3.2.P.8 (Product stability Data)

- a) Limited stability data is available on HAS 5% and HAS 25% final products. Please provide updated drug product stability data for all manufacturing scale and pilot batches for both 5% and 25% HAS.
- b) In order to review the BPL established sampling and testing arrangement, please provide stability protocols SSP/00141 (manufacturing scale batches) and SSP/00138 (pilot scale batches).

Please respond to this request by May 10, 2017.

Thanks
Lorraine

Lorraine D. Wood, MS, MLS(ASCP)^{CM}

Regulatory Project Manager

Center for Biologics Evaluation and Research
Office of Blood Research and Review
U.S. Food and Drug Administration
Tel: 240-402-8439
lorraine.wood@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.